Adverse Effects of Antipsychotic Agents: Do Newer Agents Offer Advantages?

Drugs

Volumn 51, Issue 6, 1996, Pages 895-930

  Cunningham Owens, David G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BENZAMIDE DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; PHENOTHIAZINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE;

AGRANULOCYTOSIS; AKATHISIA; ALOPECIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSTONIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPENIA; PATIENT COMPLIANCE; QUALITY OF LIFE; RASH; RETINOPATHY; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; TACHYCARDIA; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA;

EID: 0029883228     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651060-00001     Document Type: Review

References (195)

1. Swazey JP. Chlorpromazine in psychiatry: a study of therapeutic innovation. Cambridge (MA): MIT Press, 1974
2. Davis JM, Garver DL. Neuroleptics: clinical use in psychiatry. In: Iverson L, Iverson S, Snyder S, editors. Handbook of psychopharmacology. New York and London: Plenum Press, 1978: 129-64
3. Davis JM. Recent developments in the drug treatment of schizophrenia. Am J Psychiatry 1976; 133: 208-14
4. Tuma AH, May PRA. And if that doesn't work, what next? A study of treatment failures in schizophrenia. J Nerv Ment Dis 1979; 167: 566-71
5. Kane JM, Lieberman JA. Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY, editor. Psychopharmacology - the third generation of progress. New York: Raven Press, 1987: 1103-9
6. Strauss J, Carpenter W. The prediction of outcome in schizophrenia: I. Characteristics of outcome. Arch Gen Psychiatry 1972; 27: 739-46
7. Strauss J, Carpenter W. The prediction of outcome in schizophrenia: II. Relationships between predictor and outcome variables. Arch Gen Psychiatry 1974; 31; 37-42
8. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
9. Sommers AA. 'Negative symptoms': conceptual and methodological problems. Schizophr Bull 1985; 11: 364-74
10. Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985; 11: 440-52
11. Goldberg S. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 1985; 11: 453-6
12. Meltzer H, Sommers AA, Luchins DJ. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 1986; 6: 329-38
13. Breier A, Wolkowitz OM, Doran AR, et al. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 1987; 144: 1549-55
14. Moller HJ. Neuroleptic treatment of negative symptoms in schizophrenic patients: efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 1993; 3: 1-11
15. Edwards JG. The untoward effects of antipsychotic drugs: pathogenesis and management. In: Bradley PB, Hirsch SR, editors. The psychopharmacology and treatment of schizophrenia. Oxford: Oxford University Press, 1986: 403-41
16. Simpson GM, Jefferson J, Davis J, et al. Report of the American Psychiatric Association Task Force on Sudden Death. Washington (DC): American Psychiatric Association, 1987
17. Mehtonen O-P, Aranko K, Malkonen L, et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991; 84: 58-64
18. Gould RJ, Murphy KMM, Reynold IJ, et al. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci USA 1983; 80: 5122-5
19. Gould RJ, Murphy KMM, Reynolds IJ, et al. Calcium channel blockade: possible explanation for thioridazine's periphehral side effects. Am J Psychiatry 1984; 141; 352-7
20. Liberatore M, Robinson D. Torsades de pointes: a mechanism for sudden death associated with neuroleptic drug therapy. J Clin Psychopharmacol 1984; 4; 143-6
21. Fulop G, Phillips R, Shapiro A, et al. ECG changes during haloperidol and pimozide treatment for Tourette's disorder. Am J Psychiatry 1987; 144: 673-5
22. Donatini B, Le Blaye I, Krupp P. Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine. Cardiology 1992; 81: 340-1
23. Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13: 128-32
24. Wilt J, Minnema A, Johnson R, et al. Torsades de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119: 391-4
25. Cold J, Wells B, Froemming J. Seizure activity associated with antipsychotic therapy. DICP 1990; 24: 601-6
26. Levinson D, Simpson G. Neuroleptic-induced extrapyramidal symptoms with fever: heterogeneity of the 'neuroleptic malignant syndrome'. Arch Gen Psychiatry 1986; 43: 839-48
27. Keck P, Pope H, Cohen B, et al. Risk factors for neuroleptic malignant syndrome: a case control study. Arch Gen Psychiatry 1989; 46: 914-8
28. Deng MZ, Chen GC, Phillips MR. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychiatry 1990; 147: 1149-55
29. Hollister LE. Complications from the use of tranquillising drugs. N Engl J Med 1957; 257: 170-7
30. Hollister LE, Eikenberry OT, Raffel S. Chlorpromazine in non-psychotic patients with pulmonary tuberculosis. Am Rev Respir Dis 1960; 81: 562-6
31. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 1994; 89 (380): 8-13
32. Singh MM, Kay SR. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biol Psychiatry 1979; 14: 277-94
33. Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-90
34. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347-52
35. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609-18
36. NIDS Working Group. Neuroleptic-induced deficit syndrome (NIDS). J Clin Psychiatry 1993; 54: 493-500
37. Schooler NR. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand 1994; 89 Suppl. 380: 21-6
38. Caldwell AE. History of Psychopharmacology. In: Clark WG, del Giudice J, editors. Principles of psychopharmacology. New York: Academic Press, 1978: 10-40
39. Donlon P, Hopkin J, Tupin J, et al. Haloperidol for acute schizophrenic patients: an evaluation of three oral regimes. Arch Gen Psychiatry 1980; 37: 691-5
40. Neborsky R, Janowsky D, Munson E, et al. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol - behavioural considerations. Arch Gen Psychiatry 1981; 38: 195-9
41. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322-8
42. Davis JM. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 1976; 33: 858-61
43. Wyatt RJ. Biochemistry and schizophrenia (Part IV): the neuroleptics - their mechanism of action: a review of the biochemical literature. Psychopharmacol Bull 1976; 12: 5-50
44. Rev M-J, Schultz P, Costa C, et al. Guidelines for the dosage of neuroleptics: I. Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 1989; 4: 95-104
45. Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991; 48: 166-70
46. Jann M, Ereshefsky L, Saklad S. Clinical pharmacokinetics of depot antipsychotics. Clin Pharmacokinet 1985; 10: 315-33
47. Cohen BM, Baldessarini RJ, Campbell A, et al. Persistence of antipsychotic drug levels and effects. In: Tamminga CA, Schultz SC, editors Advances in neuropsychiatry and psychopharmacology. Vol. 1. Schizophrenia research. New York: Raven Press, 1991: 277-84
48. Waddington JL, Daly SA. The status of 'second generation' selective D1 dopamine receptor antagonists as putative atypical antipsychotic agents. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1992: 109-16
49. Clark D, Hjorth S, Carlsson A. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. J Neural Transm 1985; 62: 1-52
50. Seyfried CA, Haase AF, Bottcher H. Presynaptic D2 receptor selectivity of roxindole (EMD 48 980). In: Tamminga CA, Schultz SC, editors. Advances in neuropsychiatry and psychopharmacology. Vol. 1. Schizophrenia research. New York: Raven Press, 1991: 317-22
51. Wiedemann K, Krieg J-C, Loycke A, et al. Novel dopamine autoreceptor agonists B-HT 920 and EMD 49980 in the treatment of patients with schizophrenia. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1992: 91-8
52. Klimke A. Klieser E. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Pharmacopsychiatry 1991; 24: 107-12
53. Schwartz J-C, Giros B, Martres M-P, et al. The dopamine receptor family: molecular biology and pharmacology. Semin Neurosci 1992; 4: 99-108
54. Deutsch SI, Mastropaolo J, Schwartz BI, et al. A 'glutamatergic hypothesis'of schizophrenia. Clin Neuropharmacol 1989; 12: 1-13
55. Walker JM, Bowen WD, Walker FO, et al. Sigma receptors: biology and function. Pharmacol Rev 1990; 42: 355-402
56. Meltzer H, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-46
57. Casey DE. What makes a neuroleptic atypical? In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1992: 241-51
58. Seeman P. Receptor selectivities of atypical neuroleptics. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1992: 145-54
59. Jackson DM, Ryan C, Evenden J, et al. Preclinical findings with new antipsychotic agents: what makes them atypical? Acta Psychiatr Scand 1994; 89 Suppl. 380: 41-8
60. Wetzel H, Wiedemann K, Holsboer F, et al. Savoxepine: invalidation of an 'atypical' neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients. Psychopharmacology 1991; 103: 280-3
61. Owen RR, Cole JO. Molindone hydrochloride: a review of laboratory and clinical findings. J Clin Psychopharmacol 1989; 9: 268-76
62. Bjerkenstedt L. Melperone in the treatment of schizophrenia. Acta Psychiatr Scand Suppl 1989; 352: 35-9
63. Lal S, Nair NPV. Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatr Scand 1992; 85: 243-5
64. Fleischhacker WW, Barnes C, Stuppack CH, et al. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 1989; 25: 97-100
65. Moller HJ, Kissling W, Dietzfelbinger T, et al. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot study. Pharmacopsychiatry 1989; 22: 38-41
66. Bischoff S. Towards the understanding of the neuroanatomical substrate of schizophrenia: the contribution of savoxepine. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1992: 117-34
67. Svartengren J, Simonsson P. Receptor binding properties of amperozide. Pharmacol Toxicol 1990; 66 Suppl. 1: 8-11
68. Axelsson R, Nilsson A, Christensson E, et al. Effects of amperozide in schizophrenia: an open study of a potent 5-HT2 receptor antagonist. Psychopharmacology 1991; 104: 287-92
69. Goldstein JM. Pre-clinical pharmacology on new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 1995; 4: 291-8
70. Mann K, Bartels M, Bauer H, et al. Amisulpride - an open clinical study of a new benzamide in schizophrenic patients. Pharmacopsychiatry 1984; 17: 111-5
71. Lewander T, Uppfeldt G, Kohler C, et al. Remoxipride and raclopride: pharmacological background and clinical outcome. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press 1992; 67-78
72. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992; 160 Suppl. 17: 5-11
73. Van Tol H, Bunzow J, Guan H-C, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-4
74. La Hoste GJ, O'Dell SJ, Widmark CB, et al. Differential changes in dopamine and serotonin receptors induced by clozapine and haloperidol. In: Tamminga CA, Schultz SC, editors. Advances in neuropsychiatry and psychopharmacology. Vol. 1. Schizophrenia research. New York: Raven Press. 1991: 351-62
75. Farde L, Nordstrom A-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992; 160 Suppl. 17: 30-3
76. Farde L, Nordstrom A-L, Wiesel F-A, et al. Positron emission tomographic analysis of central D1 and D2 dopamine-receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538-44
77. Farde L, Nordstrom A-L, Nyberg G, et al. D1, D2 and 5HT2 receptor occupancy in clozapine treated patients. J Clin Psychiatry 1994; 55: 9 Suppl. B: 67-9
78. Baldessarini RJ, Frankenburg FR, Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746-54
79. Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992; 160 Suppl. 17: 22-9
80. Baldessarini RJ, Huston-Lyons D, Campbell A, et al. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 1992; 160 Suppl. 17: 12-6
81. Singer K, Lam CM. Evaluation of Leponex (clozapine) in schizophrenia with acute symptomatology. J Int Med Res 1973; 1: 627-9
82. Singer K, Law SK. A double-blind comparison of clozapine (Leponex) and chlorpromazine in schizophrenia of acute symptomatology. J Int Med Res 1974; 2: 433-5
83. Ekblom B, Haggstrom JE. Clozapine (Leponex)compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 1974; 16: 945-57
84. Chiu E, Burrows G, Stevenson J. Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness. Aust NZ J Psychiatry 1976; 10: 343-7
85. Guirguis E, Voineskos G, Gray J, et al. Clozapine (Leponex) vs chlorpromazine (Largactil) in acute schizophrenia (a double-blind controlled study). Curr Ther Res 1977; 21: 707-19
86. Shopsin B, Klein H, Aaronsom M, et al. Clozapine, chlorpromazine and placebo in newly hospitalised acutely schizophrenic patients. Arch Gen Psychiatry 1979; 36: 657-64
87. Juul Povlsen U, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71: 176-85
88. Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77: 524-9
89. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160 Suppl. 17: 46-53
90. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744-52
91. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892-7
92. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-90
93. Overall JE, Gorham DE. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812
94. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant schizophrenic patients: preliminary report. Psychopharmacology 1989; 99: S68-72
95. Pickar D, Owen R, Litman R, et al. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345-53
96. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-6
97. Szymanski S, Masiar S, Mayerhoff D, et al. Clozapine response in treatment-refractory first episode schizophrenia. Biol Psychiatry 1994; 35: 278-80
98. de Leon J, Simpson G. Do schizophrenic negative symptoms respond to neuroleptics? Int Psych 1991; 7: 39-47
99. Working Group on Negative Symptoms in Schizophrenia. Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology 1994; 115: 221-8
100. Miller DD, Perry PJ, Cadoret RJ, et al. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35: 8-15
101. Andreasen NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982; 39: 784-8
102. Simpson G, Angus JA. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212 Suppl.: 11-9
103. Kane JM, Safferman AZ, Pollack S, et al. Clozapine, negative symptoms and extrapyramidal side effects. J Clin Psychiatry 1994; 55: 9.Suppl. B: 74-7
104. Carpenter WT, Heinrich DW, Waginan AMI. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-83
105. Grohmann R, Ruther E, Sassim N. Adverse effects of clozapine. Psychopharmacology 1989; 99 Suppl.: S101-4
106. Naber D, Holzbach R, Perro C, et al. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992; 160 Suppl. 17 54-9
107. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329-38
108. Fitton A, Heel RC Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990; 40: 722-47
109. Centorrino F, Baldessarini RJ, Kando JC, et al. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 14: 119-25
110. Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 1964; 11: 182-9
111. Holden JMC, Holden UP. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics 1979; 11: 551-61
112. Harris E, Eth S. Weight gain during neuroleptic treatment. Int J Nurs Stud 1981; 18: 171-5
113. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214-7
114. Ziegler J, Behar D. Clozapine-induced priapism. Am J Psychiatry 1992; 149: 272-3
115. Alvir J, Lieberman J, Safferman A, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7
116. Alvir J, Lieberman J. A re-evaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. J Clin Psychopharmacol 1994; 14: 87-9
117. Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry 1993; 54: 466-9
118. Safferman A, Lieberman J, Alvir J, et al. Rechallenge in clozapine-induced agramilucytosis. Lancet 1992; 339: 1246-7
119. Lieberman JA, Johns C, Kane J, et al. Clozapine-induced agranulocytosis: non- cross reactivity with other psychotropic drugs. J Clin Psychiatry 1988; 49: 271-7
120. Bauer M, Mackert A. Clozapine treatment after agranulocytosis induced by classic neuroleptic. J Clin Psychopharmacol 1994; 14: 71-3
121. Gerson SL, G-CSF and the management of clozapine-induced agranulocylosis. J Clin Psychiatry 1994; 55: 9 Suppl. B: 139-42
122. Pisciotta V. Drug-induced agranulocytosis. Drugs 1978; 15: 132-43
123. Mandell A, Gross M. Agranulocytosis and phenothiazines. Dis Nerv Syst 1968; 29: 32-6
124. Litvak R, Kaelbling R. Agranulocytosis, leukopenia and psychotropic drugs. Arch Gen Psychiatry 1971; 24: 265-7
125. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia - observations from human and animal model studies. J Clin Psychiatry 1994; 55 9 Suppl. B: 102-6
126. Naber D, Hippius H. The European experience with use of clozapine. Hosp Community Psychiatry 1990; 41: 886-90
127. Owen RR, Beake BJ, Marby D, et al. Response to clozapine in chronic psychotic patients. Psychopharmacol Bull 1989; 25: 253-6
128. Kastrup O, Gastpar M, Schwartz M. Acute dystonia due to dozapine. J Neurol Neurosurg Psychiatry 1994; 57: 119
129. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: S47-53
130. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994; 55: 9 Suppl. B: 107-9
131. Claghorn J, Honigfeld G, Abuzzahab FS, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377-84
132. Cohen BM, Keck PE, Satlin A, et al. Prevalence and seventy of akathisia in patients on clozapine. Biol Psychiatry 1991; 29: 1215-9
133. Safferman AZ, Lieberman JA, Pollack S, et al. Akathisia and clozapine treatment. J Clin Psychopharmacol 1993; 13: 286-7
134. Roy Chengappa KN, Shelton MD, Baker RW, et al. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994; 55: 142-5
135. Levin H, Roy Chengappa KN, Kambhampati R, et al. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53: 248-51
136. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994; 35: 886-7
137. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503-10
138. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind propsective trial of high dosage trihexyphenidyl. Neurology 1986; 36: 160-4
139. Lewander T, Westerbergh S-E, Morrison D. Clinical profile of remoxipride a combined analysis of a comparative, double-blind multicentre trial programme. Acta Psychiatr Scand 1990; 82 Suppl. 358: 92-8
140. Ogren SO Hall H. Comparison of the effects of different substituted benzamides on dopamine receptor function in the rat. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1992: 59-66
141. Ogren S-O, Florvall L, Hall H, et al. Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand 1990; 82 Suppl. 358: 21-6
142. Kohler C, Hall H, Magnusson O, et al. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr Scand 1990; 82 Suppl. 358: 27-36
143. McCreadie R, Todd N, Livingston M, et al. A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand 1988; 78: 49-56
144. Lapierre YD, Nair N, Chouinard G, et al. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia - a Canadian multicentre trial. Acta Psychiatr Scand 1990; 82 Suppl. 358: 72-6
145. Patris M, Agussol P, Alby JM, et al. A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatr Scand 1990; 82 Suppl. 358: 78-82
146. Anlfors U, Rimon R, Appelberg B, et al. Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Acta Psyciatr Scand 1990; 82 Suppl. 358: 98-103
147. Andersen J, Korner A, Ostergaard P, et al. A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 82 Suppl. 358: 104-7
148. den Boer J, Ravelli D, Huisman J, et al. A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. Acta Psychiatr Scand 1990; 82 Suppl. 358: 108-10
149. Chouinard G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 1990; 82 Suppl. 358: 111-9
150. Deo R, Soni S, Rastogi S, et al. Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. Acta Psychiatr Scand 1990; 82 Suppl. 358: 120-4
151. Laux G, Klieser E, Schroder H, et al. A double-blind multicentre study comparing remoxipride, two and three doses daily, with haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 82 Suppl. 358: 125-9
152. Lindstrom L, Wieselgren I-M, Struwe G, et al. A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 82 Suppl. 358: 130-5
153. Mendlewicz J, de Bleeker E, Cosyns P, et al. A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Acta Psychiatr Scand 1990; 82 Suppl. 358: 138-41
154. Pflug B, Bartels M, Bauer H, et al. A double-blind multicentre study comparing remoxipride controlled release formulation with haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 82 Suppl. 358: 142-6
155. Keks N, McGrath J, Lambert T, et al. The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand 1994; 90: 358-65
156. Kahn J-P, Laxenaire M, Burnat G, et al. Remoxipride in acute psychosis: intramuscular followed by oral treatment compared to haloperidol, a double-blind, multicentre trial. Hum Psychopharmacol 1994; 9: 79-92
157. King DJ, Blomqvist M, Cooper SJ, et al. A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia. Psychopharmacology 1992; 107: 175-9
158. Walinder J, Holm AC. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Acta Psychiatr Scand 1990; 82. Suppl. 358: 158-63
159. Morrison D, Englund A, Lawrie V, et al. Safety evaluation in both short- and long- term treatment of schizophrenia with remoxipride. Acta Psychiatr Scand 1990; 82 Suppl. 358: 164-9
160. Farde L, Wiesel F, Jansson P, et al. An open label trial of raclopride in acute schizophrenia: confirmation of D2 dopamine receptor occupancy by PET. Psychopharmacology 1988; 94: 1-7
161. British Isles Raclopride Study Group. A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. Acta Psychiatr Scand 1992; 86: 391-8
162. Delcker A, Schoon ML, Oczkowski B, et al. Amisulpride versus haloperidol in treatment of schizophrenic patients - results of a double-blind study. Pharmacopsychiatry 1990; 23: 125-30
163. Boyer P, Lecrubier Y, Puech A-J, et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995; 166: 68-72
164. Paillere-Martinot ML, Lecrubier Y, Martinot JL, et al. Improvement in some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995; 152: 130-3
165. Leysen J, Janssen P, Megens A, et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994; 55 Suppl.: 5-12
166. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995: 15 Suppl. 1: 4S-10S
167. Strauss WH, Klieser E. Psychotropic effects of ritanserin, a selective S2 antagonist: an open study. Eur Neuropsychopharmacol 1991; 1: 101-5
168. Wiesel EA, Nordstrom A-L, Farde L, et al. An open clinical trial and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 1994; 114: 31-8
169. Pangalila-Ratu Langi EA, Jansen AAI, Ritanserin in the treatment of generalised anxiety disorders: a placebo-controlled trial. Hum Psychopharmacol 1988; 3: 207-12
170. Bersani G, Pozzi E, Marini S, et al. 5HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991; 83: 244-8
171. Miller C, Fleischhacker W, Ehrmann H, et al. Treatment of neuroleptic induced akathisia with the 5HT2 antagonist ritanserin. Psychopharmacol Bull 1990; 26: 373-6
172. Bersani G, Grispini A, Marini S, et al. 5HT2 antagonist ritanserin in neuroleptic- induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13: 500-6
173. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76
174. Chouinard G, Ross-Chouinard A, Annable L, et al. The Extrapyramidal Symptom Rating scale. Can J Neurol Sci 1980; 7: 233
175. Lingjaerde O, Ahlfors U, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 76 Suppl. 334: 1-100
176. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213-8
177. Chouinard G, Jones B, Remington G, et al. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40
178. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
179. Peuskens J, on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
180. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre, double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295-305
181. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidot in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26: 121-4
182. Hoyberg O, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395-402
183. Klieser H, Lehmann B, Kinzler E, et al. Randomised, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psycopharmacol 1995; 15 Suppl. 1: 45S-51S
184. Moller HJ, Muller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients - a re-evaluation of the North American Risperidone Study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45-9
185. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994; 344: 1228-9
186. Raitasuo V, Valasja R. Elomaa E. Risperidone-induced neuroleptic malignant syndrome in a young patient. Lancet 1994; 344: 1705
187. Lee H, Ryan J, Mullett G, et al. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical anlipsychotic agent. Hum Psychopharmacol 1994; 9: 303-5
188. Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994; 55 Suppl.: 29-35
189. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-7
190. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicentre Risperidone Study. J Clin Psychopharmacol 1995; 15 Suppl. 1: 36S-44S
191. Owens DGC, Johnstone EC, Frith CD. Chronic schizophrenia and the defect state: a case of terminological inexactitude. In: Schiff AA, Roth M, Freeman HL, editors. Schizophrenia: new pharmacological and clinical developments. London: Royal Society of Medicine. 1985: 5-14
192. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-51
193. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917-26
194. Addington D. The use of placebos in clinical trials for acute schizophrenia. Can J Psychiatry 1995; 40: 171-6
195. Owens DGC. Advances in psychopharmacology - schizophrenia. In: Johnstone EC, editor. British Medical Bulletin. London: Royal Society of Medicine. In press